Showing results (81-90 of 95) with videos related to
Sort By:
Pageof 10
British Journal of Cancer|May 16, 2019
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphomaAnke Maes, Ken Maes, Hendrik De Raeve, et al.Journal for Immunotherapy of Cancer|April 29, 2025
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapyArne Van der Vreken, Fabien Thery, Chenggong Tu, et al.Blood Cancer Journal|December 18, 2023
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid LeukemiaRong Fan, Hatice Satilmis, Niels Vandewalle, et al.The Journal of Pathology|October 17, 2022
Targeting the β<sub>2</sub> -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolismHatice Satilmis, Emma Verheye, Philip Vlummens, et al.Theranostics|May 22, 2024
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid LeukemiaNiels Vandewalle, Hatice Satilmis, Emma Verheye, et al.Cancer Research|December 21, 2017
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant ProgressionEva De Smedt, Ken Maes, Stefaan Verhulst, et al.Journal for Immunotherapy of Cancer|January 17, 2023
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myelomaRong Fan, Hatice Satilmis, Niels Vandewalle, et al.Pediatric Nephrology (Berlin, Germany)|March 17, 2023
Illness-related parental stress and quality of life in children with kidney diseasesElke De Bruyne, Lore Willem, Koen Van Hoeck, et al.British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.Frontiers in Immunology|November 30, 2023
RNA-sequencing based first choice of treatment and determination of risk in multiple myelomaMartina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, et al.Pageof 10